SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Adamas Pharmaceuticals Q1 EPS $(0.590) Beats $(0.790) Estimate, Sales $14.481M Miss $15.360M Estimate

Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.590) per share which beat the analyst consensus estimate of $(0.790) by 25.32 percent. This is a 45.37 percent increase over losses of $(1.080) per

Benzinga · 05/07/2020 20:14

Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.590) per share which beat the analyst consensus estimate of $(0.790) by 25.32 percent. This is a 45.37 percent increase over losses of $(1.080) per share from the same period last year. The company reported quarterly sales of $14.481 million which missed the analyst consensus estimate of $15.360 million by 5.72 percent. This is a 24.14 percent increase over sales of $11.665 million the same period last year.